Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 302.15
-3.80 (-1.24%)
At close: Mar 27, 2026
Cohance Lifesciences Market Cap
Cohance Lifesciences has a market cap or net worth of 115.8 billion as of March 27, 2026. Its market cap has decreased by -60.94% in one year.
Market Cap
115.80B
Enterprise Value
117.67B
Revenue
10.79B
Ranking
n/a
PE Ratio
190.97
Stock Price
302.15
Market Cap Chart
Since March 9, 2020, Cohance Lifesciences's market cap has increased from 33.71M to 115.80B, an increase of 343,478.32%. That is a compound annual growth rate of 283.94%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 115.80B | -42.74% |
| Dec 31, 2025 | 202.22B | -30.24% |
| Dec 31, 2024 | 289.89B | 57.55% |
| Dec 29, 2023 | 184.00B | 46.05% |
| Dec 30, 2022 | 125.98B | 0.33% |
| Dec 31, 2021 | 125.56B | 9.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Mar 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| J. B. Chemicals & Pharmaceuticals | 334.36B |
| AstraZeneca Pharma India | 210.39B |
| Granules India | 155.80B |
| Jubilant Pharmova | 136.99B |
| Rubicon Research | 127.45B |
| Caplin Point Laboratories | 121.29B |
| CORONA Remedies | 96.79B |
| Viyash Scientific | 84.52B |